Apomorphine sublingual film - Sunovion Pharmaceuticals

Drug Profile

Apomorphine sublingual film - Sunovion Pharmaceuticals

Alternative Names: APL-130277

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adagio Pharmaceuticals
  • Developer Sunovion Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Parkinson's disease

Most Recent Events

  • 03 Aug 2017 Sunovion Pharmaceuticals initiates enrolment in a phase II trial in Parkinson's disease in USA (Sublingual) (NCT03187301)
  • 22 Mar 2017 Sunovion Pharmaceuticals initiates a phase III trial in Parkinson's disease in United Kingdom (EudraCT2016-003456-70)
  • 02 Mar 2017 Interim efficacy data from a long-term phase III trial in Parkinson's disease presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top